Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase NA × Adenocarcinoma of Lung × Gefitinib × Clear all

Phase

Phase 2 10 Phase 3 4 Phase NA 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 4 Lung Neoplasms 2 Tongue Neoplasms 1 Thyroid Neoplasms 1 Thyroid Carcinoma, Anaplastic 1 Thyroid Cancer, Papillary 1 Squamous Cell Carcinoma of Head and Neck 1 Salivary Gland Neoplasms 1 Parathyroid Neoplasms 1 Non-squamous Non-small Cell Lung Cancer 1 Non-Small-Cell Lung 1 NSCLC 1 Gastrointestinal Neoplasms 1 Esthesioneuroblastoma, Olfactory 1 EGFR Mutation Positive Non-small Cell Lung Cancer 1 Carcinoma, Medullary 1 Carcinoma, Hepatocellular 1 Adenocarcinoma, Follicular 1 Adenocarcinoma of Lung 1

Interventions

tislelizumab 2 Early Intervention, Educational 2 Carboplatin 2 Taxes 1 Standard of Care 1 Smoking Devices 1 Radiotherapy, Image-Guided 1 Radiotherapy, Conformal 1 Radiotherapy 1 Radiosurgery 1 Radiofrequency Ablation 1 Practice Guidelines as Topic 1 Platinum 1 Pemetrexed 1 Paclitaxel 1 Morphine 1 Methods 1 Mastectomy, Segmental 1 Magnetic Resonance Spectroscopy 1 Lymph Node Excision 1 Gefitinib 1 Fluorodeoxyglucose F18 1 Exercise 1 Diet, Ketogenic 1 Bupivacaine 1 Anti-Inflammatory Agents, Non-Steroidal 1 Anterior Temporal Lobectomy 1 Acetaminophen 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02282267 2017-02-24

Benefit

Peking University Cancer Hospital & Institute

Phase NA Unknown

Adenocarcinoma of Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡